Although scaling and root planning (SRP) is effective at reducing plaque and some bacteria, it doesn’t kill all of the bacteria that cause periodontal disease. SRP is a mechanical procedure and the instruments used to perform SRP cannot always reach the bacteria that reside at the bottom of deep or difficult-to-reach periodontal pockets. For these pockets, dental professionals often add a locally administered antibiotic (LAA) such as ARESTIN® (minocycline hydrochloride) Microspheres, 1mg to the SRP procedure.
This comprehensive approach provides patients with two therapies that work simultaneously (ARESTIN® + SRP) to help kill the harmful bacteria that cause periodontal disease-so that the infection becomes more easily managed and won’t immediately return.
Infected areas in your gums
Infected pockets inside your gums require treatment before periodontal disease causes further damage. ARESTIN® is indicated as an adjunct to scaling and root planning (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program which includes good oral hygiene, and SRP.
ARESTIN® is a small amount of powder that is easily applied by a dental professional:
Clinical studies show that ARESTIN® plus SRP is more effective than SRP alone at shrinking the size of infected periodontal pockets, killing the bacteria associated with periodontal disease, and reducing bleeding on probing of the gums
ARESTIN® remains in the pocket for up to 21 days—to help ensure continued treatment
ARESTIN® is safe and easy for your dental professional to administer
HOW IT WORKS
Give your gums a fighting chance
Even though scaling and root planning (SRP) removes a great deal of bacteria that cause periodontal infection, the instruments used during this mechanical procedure can’t always reach the bacteria that hide in the bottom of pockets or in difficult-to-reach areas.
That’s why a dental healthcare team often decides to add a locally administered antibiotic (LAA) such as ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg.
Minocycline Microspheres make it different ARESTIN® uses Microsphere technology to easily and effectively kill the bacteria that cause periodontal disease. ARESTIN® is safe and easy for your dental professional to administer.
ARESTIN® is a small amount of antibiotic powder that is placed inside infected periodontal pockets just after your dental professional finishes the SRP procedure. Once ARESTIN® is inserted, it immediately adheres to the periodontal pocket. Through a process called “polymer hydrolysis”, tiny holes in the Microspheres provide “escape routes” for the drug to be slowly released and absorbed into the surrounding gum tissue. This allows for a “sustained release” of the antibiotic, meaning ARESTIN® continues to work inside your gums for up to 21 days.
Clinical studies show that ARESTIN® plus SRP is more effective at treating periodontal disease than SRP alone.
The use of a locally administered antibiotic (LAA) is not a new concept. For years, dental professionals have used antibiotics in conjunction with scaling and root planning (SRP) procedures. However, ARESTIN® (minocycline hydrochloride) Microspheres, 1 mg is the first LAA with Microspheres that has been PROVEN to be more effective than SRP alone.
Adding ARESTIN® makes a significant difference
The leading locally administered antibiotic (LAA), ARESTIN®, delivers a sustained dose of minocycline directly to infected pockets, helping to kill the bacteria that SRP can leave behind.
ARESTIN® provides safe, localized drug concentrations at the site of the infection
ARESTIN® helps maintain therapeutic drug concentrations in the periodontal pocket for up to 21 days ARESTIN® stays in place after application and does not require removal
For more information on the proven results of ARESTIN®, please visit our Clinical Resources section for dental professionals where you will find clinical data from studies with ARESTIN®.
Minimal side effects were reported in clinical studies, and those that were reported were similar to placebo (no treatment at all). In key clinical trials, the most common adverse events associated with treatment were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%).